MarketPulse

NLRP3 inhibitor

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

BioAge Labs to Showcase BGE-102 Progress at Major Healthcare Investor Conferences

Clinical-stage biotech BioAge Labs will present at Jefferies and Goldman Sachs healthcare conferences in June 2026, highlighting BGE-102 development progress.
BIOAinvestor conferenceclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Bioage Labs, Inc.

BioAge's BGE-102 Shows Best-in-Class Inflammation Reduction in Phase 1 Trial

BioAge's BGE-102 achieves best-in-class hsCRP reductions of ≥85% in Phase 1, with excellent tolerability. Phase 2 cardiovascular and diabetic macular edema trials planned for mid-2026.
BIOAPhase 1 clinical trialdiabetic macular edema
GlobeNewswire Inc.GlobeNewswire Inc.··Nodthera

NodThera to Present NLRP3 Drug Program at Major April Investor Conferences

NodThera, a clinical-stage NLRP3 inhibitor biotech, will present at major April 2026 investor conferences including Piper Sandler and Needham.
SNYoral therapyclinical-stage biotech